



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/04, 15/11, 1/14, G01N 33/53, C07K 14/00, 14/37, 16/00, 16/14	A1	(11) International Publication Number: WO 98/46738 (43) International Publication Date: 22 October 1998 (22.10.98)
(21) International Application Number: PCT/US98/07728 (22) International Filing Date: 15 April 1998 (15.04.98) (30) Priority Data: 60/043,332 15 April 1997 (15.04.97) US (71) Applicant: BARNES-JEWISH HOSPITAL [US/US]; 1 Barnes-Jewish Hospital Plaza, St. Louis, MO 63110 (US). (72) Inventors: WEIL, Gary, J.; 1 Barnes-Jewish Hospital Plaza, St. Louis, MO 63110 (US). CHANDRASHEKAR, Ra- maswamy; 1 Barnes-Jewish Hospital Plaza, St. Louis, MO 63110 (US). (74) Agents: STONE, Paul, A. et al.; Senniger, Powers, Leavitt & Roedel, 16th floor, One Metropolitan Square, St. Louis, MO 63102 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i>
(54) Title: METHODS OF OBTAINING ANTIGENS SPECIFIC FOR FUNGI, ANTIBODIES FOR SUCH ANTIGENS, AND DIAGNOSIS OF DISEASE USING SUCH ANTIGENS AND/OR ANTIBODIES		
(57) Abstract A method for identifying a protein antigen to a target fungus is disclosed. The method comprises screening expressed proteins from a cDNA gene expression library with antisera to the target fungus and cross-screening with antisera to a nontarget fungus. Antibodies to the protein antigen are also disclosed. Methods for detecting the presence or absence of the antibodies or of the protein antigen are also disclosed, as well as kits for performing such assays. In preferred embodiments, the target fungus is <i>H. capsulatum</i> .		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

METHODS OF OBTAINING ANTIGENS SPECIFIC FOR FUNGI, ANTIBODIES
FOR SUCH ANTIGENS, AND DIAGNOSIS OF DISEASE USING SUCH
ANTIGENS AND/OR ANTIBODIES

BACKGROUND OF THE INVENTION

5 The present invention generally relates to methods
of detection of a fungus and fungal infections through
the use of protein antigens specific for the fungus.
This invention also relates methods for identifying such
antigens, to antibodies raised against these antigens, to
10 the use of such antigens and/or antibodies in assay
methods for the determination of the presence of the
fungus or diseases caused by the fungus in humans, other
animals, plants, food, feed, and inorganic materials such
as soil or air. The invention also relates to assay kits
15 suitable for carrying out such diagnostic methods. In a
preferred embodiment, the invention particularly relates
to the fungus *Histoplasma capsulatum* (hereinafter *H.*
capsulatum) and the infections caused by this fungus,
histoplasmosis.

20 Rapid, positive detection of fungi has long been
difficult because antibodies which are made to fungi are
generally nonspecific. That is, these antibodies often
cross-react with other fungi. This problem is thought to
be due to the abundance of highly immunogenic
25 carbohydrate antigenic determinants which are present,
for example, in the fungal cell wall. The cross-reactive
nature of fungal antigens is exemplified by previously
known approaches to develop diagnostic methods to
identify infections of *H. capsulatum*.

30 *H. capsulatum* is a pathogenic dimorphic fungus that
grows as multicellular mycelia in nature and as
unicellular budding yeasts in humans and animals.
Inhalation of airborne propagules results in a
morphological transformation to the yeast form which
35 causes pulmonary infection and occasional progressive
disease, particularly in immunosuppressed patients.

Histoplasmosis is highly endemic in the Ohio and Mississippi valleys in the United States, and it is also widely distributed in Latin America, southern Europe, Asia, Australia and Africa.

5 The diagnosis of histoplasmosis in humans is often suggested by results of a careful clinical evaluation and radiologic studies, but laboratory tests are necessary to confirm the diagnosis. Isolation of the organism from blood or tissue provides a definitive diagnosis.

10 Serological tests are also important diagnostic tools for histoplasmosis. The most widely available tests are the immunodiffusion assay, which detects antibodies to heat-sensitive glycoproteins called H and M antigens, and the more sensitive complement fixation test, which is
15 traditionally performed with yeast and mycelial antigens. More sensitive antibody assays such as radio-immunoassay and enzyme immunoassay have been used to detect IgM and IgG antibodies to crude fungal extracts. See, generally, references 39, 40, and 41.

20 Attempts to develop antibody serology tests for diagnosis of histoplasmosis have been hampered by poor specificity caused by immunologic cross-reactivity between various fungal species. The problem of cross-reactivity to other fungi may be worsened in the
25 diagnosis of histoplasmosis by the fact that *H. capsulatum* is taxonomically closely related to two other pathogens, *Coccidioides immitis*, and *Blastomyces dermatitidis*. See Kwon-Chung, Science 177:368-369 (1972), and McGinnis et al., Mycotaxon 8:157-164 (1979).
30 These fungi, which may be present along with *H. capsulatum*, cause coccidiomycosis and blastomycosis, diseases with etiologies similar to histoplasmosis. While *H. capsulatum*, *C. immitis*, and *B. dermatitidis* are known as imperfect fungi due to their rare or nonexistent
35 sexual stage, studies have shown that *H. capsulatum* and *B. dermatitidis* are in the same telomorph genus,

Ajellomyces, and those two fungi may be in the same taxonomic family as *C. immitis*, the Gymnoascaceae, order Onygenales, of the Ascomycetes. Another fungal pathogen, *Candida* sp., is also an ascomycete. See generally, Kwan-Chung et al., Medical Mycology, Lea and Febiger, Philadelphia (1992), which is incorporated by reference.

In view of the cross-reactivity and poor specificity common with fungal antibodies, there is a need for improved methods for identifying antigens which are specific to a target fungus. Such antigens are useful in diagnosis of diseases caused by the fungus and in determining the presence or absence of the fungus.

SUMMARY OF THE INVENTION

It is therefore an object of the invention to develop methods suitable for identifying protein antigens specific to a target fungus and, particularly, to *H. capsulatum*.

It is also an object to develop assays and assay reagents having improved specificity for identifying target fungal antigens and antibodies, and for the diagnosis of diseases caused by a target fungus and, particularly, by *H. capsulatum*.

Therefore, the present invention is directed to a method for identifying a protein antigen of a target fungus. A cDNA gene expression library is obtained for the target fungus, and the library is expressed to form an array of target-fungus proteins. Antisera to the target fungus and to a nontarget fungus are also obtained, each of which comprises antibodies to the target fungus and nontarget fungus, respectively. The nontarget fungus has at least one antigenic determinant (e.g. a protein determinant or glycoprotein determinant) in common (ie, shared with) the target fungus. A protein antigen specific to the target fungus is then identified by identifying a target-fungus protein which is bound by

the antibodies to the target fungus, but which is not substantially bound by antibodies to the nontarget fungus. That is, while antibodies to the target fungus are immunoreactive with the identified protein antigen, antibodies to the nontarget fungus are not substantially immunoreactive with the identified protein antigen.

The invention is also directed to substantially purified or isolated antibodies or antibody fragments. In one embodiment, the antibody or antibody fragment is immunoreactive with a protein antigen identified according to the aforementioned method. In another embodiment, the antibody or antibody fragment is immunoreactive with an antigen of *H. capsulatum*, but which is not substantially immunoreactive with antigens of each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.* In a further embodiment, antibody or antibody fragment is immunoreactive with a protein antigen having the amino acid sequence set forth in SEQ ID NO: 3 or with a portion thereof that is specific to *H. capsulatum*.

The invention is directed, moreover, to a method for determining the presence or absence of a target-fungus antibody in a vertebrate such as a mammal. In one embodiment, the method comprises obtaining an antibody-containing sample from the vertebrate, contacting the sample with a target-fungus protein antigen identified according to the method of claim 1, and determining whether an antibody in the sample immunoreacts with the target-fungus protein antigen. In an alternative embodiment directed to determining the presence or absence of antibodies to *H. capsulatum* in a mammal, the method comprises obtaining an antibody-containing sample from the mammal, contacting the sample with a protein antigen of *H. capsulatum* which is bound by antibodies to *H. capsulatum* but which is not substantially bound by antibodies to each of *Coccidioides immitis*, *Blastomyces*

dermatitidis or *Candida sp.*, and determining whether an antibody in the sample immunoreacts with the protein antigen of *H. capsulatum*. In an additional embodiment for determining antibodies to *H. capsulatum*, the method comprises obtaining an antibody-containing sample from the mammal, contacting the sample with a protein antigen having an amino acid sequence as set forth in SEQ ID NO: 3, and determining whether an antibody in the sample immunoreacts with the protein antigen.

The invention is further directed to a method for determining the presence or absence of a target-fungus protein antigen in a sample. The method generally comprises obtaining a sample to be tested for the presence or absence of the target-fungus protein antigen, contacting the sample with an antibody or antibody fragment which is immunoreactive with a target-fungus protein antigen identified according to the method of claim 1, and determining whether the antibody or antibody fragment immunoreacts with the target-fungus protein antigen. As directed to determining the presence or absence of a *H. capsulatum* protein antigen in a mammal, the method comprises obtaining a sample to be tested for the presence or absence of the *H. capsulatum* protein antigen, contacting the sample with an antibody or antibody fragment which is immunoreactive with an antigen of *H. capsulatum*, but which is not substantially immunoreactive with antigens of each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.*, and determining whether the antibody or antibody fragment immunoreacts with the *H. capsulatum* protein antigen. In an alternative method for determining the presence or absence of a *H. capsulatum* protein antigen in a mammal, the method comprises obtaining a sample to be tested for the presence or absence of the *H. capsulatum* protein antigen, contacting the sample with an antibody or antibody fragment which is immunoreactive with a protein

antigen having an amino acid sequence as set forth in SEQ ID NO: 3, and determining whether the antibody or antibody fragment immunoreacts with the protein antigen.

The invention is additionally directed to a kit that
5 includes a reagent selected from, in one embodiment, one or more of the following: (i) a target-fungus protein antigen identified according to the aforementioned method, (ii) a fragment of a target-fungus protein antigen identified according to the aforementioned method
10 wherein the fragment is bound by antibodies to the target fungus but is not substantially bound by antibodies to the nontarget fungus, and (iii) a target-fungus antibody or antibody fragment which immunoreacts with a target-fungus protein antigen identified according to the
15 aforementioned method. In an alternative embodiment, the reagent is selected from one or more of the following: (i) a protein antigen of *H. capsulatum* which is bound by *H. capsulatum* antibodies but which is not substantially bound by antibodies to each of *Coccidioides immitis*,
20 *Blastomyces dermatitidis* or *Candida sp.*, (ii) a fragment of a *H. capsulatum* protein antigen wherein the fragment is bound by antibodies to *H. capsulatum* but is not substantially bound by antibodies to each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.*, and
25 (iii) an antibody or antibody fragment which is immunoreactive with a *H. capsulatum* protein antigen but which is not substantially immunoreactive with antigens of each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.*. In yet another embodiment, the reagent is
30 selected from: (i) a protein antigen having an amino acid sequence as set forth in SEQ ID NO:3, (ii) a protein antigen that includes a portion of the amino acid sequence as set forth in SEQ ID NO:3 wherein the included portion is bound by antibodies to *H. capsulatum* but is
35 not substantially bound by antibodies to each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida*

sp., (iii) an antibody or antibody fragment which is immunoreactive with a protein antigen having the amino acid sequence set forth in SEQ ID NO: 3, and (iv) an antibody or antibody fragment which is immunoreactive with a protein antigen that includes a portion of the amino acid sequence set forth in SEQ ID NO: 3 wherein the included portion is bound by antibodies to *H. capsulatum* but is not substantially bound by antibodies to each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida* sp.. The kit also includes instructions for directing the use of the reagent for determining the presence or absence of the target fungus in a sample. In one embodiment, the instructions direct the use of the reagent for determining whether a mammal is presently infected or has been previously infected with the target fungus. In another embodiment in which the reagent is an antibody, the instructions direct the use of the antibody reagent for determining the presence or absence of an antigen in a nonvertebrate sample or environment, such as a plant, food, feed, feed component, air, water, or other fluid sample.

Other features, objects and advantages of the present invention will be in part apparent to those skilled in the art and in part pointed out hereinafter. All references cited in the instant specification are incorporated by reference. Moreover, as the patent and non-patent literature relating to the subject matter disclosed and/or claimed herein is substantial, many relevant references are available to a skilled artisan that will provide further instruction with respect to such subject matter.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows a hydropathy plot of the protein encoded by GH17. Hydropathy analysis was performed by the method of Hopp and Woods. Hydropathy values were averaged for a window of six amino acid residues. Positive numbers indicate hydrophilicity. The point of highest hydrophilicity (Average hydrophilicity=2.08, between residues 155-160) is marked with a broken vertical line.

FIG. 2 shows a comparison of the deduced amino acid sequence encoded by GH17 with threonine-rich regions of: (A) cellulase from the thermophilic bacterium *Caldocellum saccharolyticum*; (B), *Leishmania* surface antigen; and (C), integumentary mucin from *Xenopus laevis* using the NCBI BLAST analysis program. Identical residues are indicated with letters, and conserved residues are marked with a (+).

FIG. 3 shows a Southern blot of genomic DNA of *H. capsulatum* probed with labeled cDNA insert from clone GH17. Genomic DNA was digested with *EcoRI* (lane 1), *PstI* (lane 2), and *SacI* (lane 3), electrophoresed on a 1% agarose gel, and transferred to nylon membrane. The membrane was probed with peroxidase-labeled cDNA insert of GH17 and washed under high-stringency conditions.

FIG. 4 shows the results of an immunoblot analysis of the immunoreactivity and specificity of the β -galactosidase fusion protein of the recombinant clone GH17. The immunoreactive fusion protein band is indicated by an arrow. FIG. 4A shows a representative immunoblot demonstrating the immunoreactivity of the fusion protein. Bacterial cell-lysates from cells infected with GH17 were separated by SDS-PAGE and electrophoretically transferred to nitrocellulose paper. The blot was developed with individual sera from patients with histoplasmosis (Lanes 1-18). 16 of 18 sera had strong antibody reactivity with the fusion protein, and

two sera were weakly reactive (Lanes 6 and 9). Lane 19 was developed with a murine monoclonal antibody to β -galactosidase. FIG. 4B demonstrates the antigenic specificity of recombinant *H. capsulatum* clone GH17 β -galactosidase fusion protein by immunoblot analysis. Lanes in various panels were developed as follows: Panel A, with sera from dogs infected with *B. dermatitidis* (n=6); B, with human sera from patients infected with *B. dermatitidis* (n=5); C, with human sera from patients infected with *Candida albicans* (n=5); D, with human sera from patients infected with *Coccidioides immitis* (n=12); E, with human histoplasmosis serum pool and anti- β -galactosidase antibody, respectively.

FIG. 5 shows an SDS-PAGE and immunoblot analysis of expression of GH17-his in pPROEX-1™ protein expression vector. In FIG. 5A, 10% SDS-PAGE was loaded with *E. coli* extract without IPTG induction (lane 1), and after IPTG induction for 3 hr (lane 2). The immunoblots were developed with human histoplasmosis serum pool (1:500), enzyme-labeled anti-human IgG secondary antibody, and substrate. FIG. 5B shows immunoblot analysis of eluted fractions of GH17-his fusion protein separated by preparative SDS-PAGE in the model 491 BioRad Prep Cell. Aliquots (10 μ l) from the Prep Cell fractions were separated by SDS-PAGE on 12% gels, immunoblotted, and developed as described for Fig. 5a. Lane 1, IPTG induced *E. coli* extract (2 μ l); Lanes 2-4 contain positive fractions from the Prep Cell.

FIG. 6 shows an immunoblot analysis of *H. capsulatum* yeast antigen extract developed with: lane 1, mouse antibody to GH17-his fusion protein (1:500); lane 2, normal mouse serum (1:500); and lane 3, mouse antibodies to *H. capsulatum* yeast extract (1:500).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is directed toward protein antigens which are specific to a target fungus, to methods of obtaining such antigens, to antibodies to such antigens, and to assays employing such antigens and antibodies.

An antigen specific to a particular target fungus is identified by a) obtaining a cDNA gene expression library for the target fungus, b) expressing target fungal proteins from the cDNA gene expression library, c) obtaining antisera to the target fungus which has antibodies to the target fungus, d) obtaining antisera to the nontarget fungus which has antibodies to the nontarget fungus and e) identifying a target-fungus protein which is bound by the antibodies to the target fungus, but which is not substantially bound by the antibodies to the nontarget fungus.

The steps of the above method need not be performed in any particular order. In a preferred embodiment of the above method, the cDNA expression library is first screened with an antisera to the target fungus. Clones which are highly reactive to the target fungus are thus identified, and these selected clones are then screened with antisera to the nontarget fungus. The clones which produce a protein which is bound by antibodies in the antisera to the target fungus but not by antibodies in the antisera to other microorganisms (e.g. nontarget fungi) are then identified. Various manipulations known in the art can utilize these clones to produce and substantially purify the protein antigens encoded by the clones. The protein antigens can then be used as discussed below.

The procedures disclosed herein which involve the molecular manipulation of nucleic acids are known to those skilled in the art. See generally Fredrick M. Ausubel et al. (1995), "Short Protocols in Molecular

Biology", John Wiley and Sons, and Joseph Sambrook et al. (1989), "Molecular Cloning, A Laboratory Manual", second ed., Cold Spring Harbor Laboratory Press.

A used herein, the term "target fungus" (pl. "target fungi") denotes any fungus for which there is a particular interest. Examples of target fungi are fungi which are pathogens of animals or plants, allergens, food spoiling agents, or food sources. Preferred target fungi include Ascomycetes. More preferred target fungi are those fungi in the genus *Gymnoascaceae*. Even more preferred fungi are those in the genus *Ajellomyces*, and the most preferred target fungus is *H. capsulatum*. A "nontarget fungus" may be any fungus that is desired to be distinguished from the target fungus, for identification or diagnostic purposes, by an immunoassay. In general, the nontarget fungus includes at least one antigenic determinant in common with the target fungus. As such, the nontarget fungus can cross react with an antibody that recognizes this shared antigenic determinant. Exemplary nontarget fungi may be selected from fungi known to cause a disease with similar symptoms as the target fungus.

The cDNA gene expression library of the target fungus may be obtained from a commercial source or prepared by methods known in the art, using an appropriate morphological stage of the target fungus. An easily culturable stage such as mycelium is preferred. Common vectors used for this purpose are plasmid, bacteriophage, and mammalian cells. A preferred expression library is one utilizing a phage such as bacteriophage λ gt11, with poly(A)+ mRNA.

The target fungus proteins are expressed by any method known in the art. For the preferred λ gt11 expression library, the proteins are generally expressed by induction with IPTG.

Antisera to the target fungus may be obtained in any manner known in the art. Preferably such antisera are obtained by preparing an antigen which will, upon immunization of an animal with the fungus, yield an
5 antisera which contains a population of antibodies which, in sum, will immunoreact to many antigens of the target fungus. An unfractionated preparation of the target fungus is thus a preferred antigen preparation. However, a fractionated preparation could also be employed. When
10 the target fungus is pathogenic to vertebrates which are capable of mounting an immunological response to the fungus, the preferred screening antisera is serum from infected individuals. A more preferred screening antisera is pooled serum from several infected
15 individuals. Antisera to the nontarget fungus can be obtained by methods similar to the methods used to prepare antisera to the target fungus.

Target-fungal proteins which are bound by the target-fungus antibodies but which are not substantially bound by the nontarget-fungus antibodies can be
20 identified by screening each of the antisera by appropriate immunological assays known in the art. The terms "immunoreact", "bind", "are bound to" or grammatical derivations thereof are used interchangeably
25 herein, and refer to the capability of an antibody or an antibody fragment to specifically attach to an antigen at the antibody's Fab binding site. Exemplary screening assays include precipitin assays and label-based assays. Preferably, the antigen is identified from the expressed
30 cDNA gene expression library by blotting the expressed proteins (e.g. from phage plaques) onto membranes then screening the membranes with the antisera made to each fungus.

The degree of immunological cross-reactivity for the
35 identified target-fungus protein (generally referred to herein as a target-fungus specific antigen) is preferably

sufficiently low so that tests that detect the antigen or antibodies to the antigen are useful for reliably distinguishing the fungus from nontarget fungi. The degree of immunological cross-reactivity with nontarget fungi and/or other microorganisms of interest, when assessed by immunoassay (for example Western blot or ELISA), is preferably less than about 10%, more preferably less than about 5%, still more preferably less than about 2%, even more preferably less than about 1%, and most preferably less than about 0.1%.

The identified target-fungus specific protein antigen is more specifically characterized as follows, with the various aspects defining the protein to be considered both independently and in combination. The target fungus-specific protein antigen is preferably substantially free from non-protein determinants such as carbohydrates, phosphorylcholine, and/or other moieties which, when attached to or otherwise associated with the protein, would reduce the immunological specificity of the protein.

The term "specific" is used herein to denote an antigen which is not present in nontarget fungi. When referring to an antibody or to an assay, "specific" denotes a substantial lack of cross-reactivity with nontarget fungi. As an example, an antigen of a target fungus which infects mammals would be specific if antibodies in serum produced by a target fungus-infected vertebrate bound to the antigen, but sera produced in vertebrates which are infected with a nontarget fungus do not substantially cross-react with the antigen. The extent of cross-reactivity can be more specifically characterized with regard to a set (ie. group or population) of samples being evaluated. In a sample population known to comprise the target-fungus antigen or antibodies to the antigen, the presence of the antigen or antibody is correctly determined in preferably at least

about 90% of the samples, more preferably in at least about 95% of the samples and most preferably in at least about 99% of the samples. Conversely, in a sample population known to both (i) lack the target fungus antigens or antibodies thereto and (ii) comprise a nontarget fungus antigen or antibodies thereto, the absence of the target fungus antigen or antibody thereto is correctly determined in preferably at least about 90% of the samples, more preferably in at least about 95% of the samples and most preferably in at least about 99% of the samples. As another example, an antigen on a plant pathogenic fungus is specific if antisera made to that antigen does not substantially cross-react with antigens on other nontarget fungi which might be present in the same environment as the plant pathogenic fungus.

Target-fungus specific protein antigens with such cross-reactivity can be varied from the identified protein antigen, but will preferably have an amino acid sequence which has a sequence identity or, alternatively, a homology of at least about 75%, more preferably at least about 90%, even more preferably at least about 95% and most preferably at least about 98% relative to the amino acid sequence of the identified protein antigen or, alternatively, as encoded by the cDNA clone thereof.

In a preferred embodiment the target fungus is *H. capsulatum*. Preferred nontarget fungi are *C. immitis*, *B. dermatitidis*, and *Candida sp.* *H. capsulatum* proteins expressed from a cDNA expression library are screened, preferably by immunoblot, against antisera to *H. capsulatum* and at least one of the nontarget fungi. The antisera are preferably provided by pooled sera from individuals infected with the target and nontarget fungi. Where the target fungus is *H. capsulatum*, a preferred protein antigen has the amino acid sequence set forth as SEQ ID NO:3. (See example). In another embodiment, the protein is a *H. capsulatum*-specific protein antigen and

has an amino acid sequence which includes at least a portion of the amino acid sequence set forth as SEQ ID NO:3 which is specific for *H. capsulatum*, the included portion being, in a preferred protein, at least 5 amino acids in length. The *H. capsulatum*-specific antigen identified in this manner is not substantially cross-reactive with antisera to the nontarget fungus. (See Example).

The target-fungus specific antigen, identified for example by the afore-described screening protocols, can be isolated and produced in substantially purified form according to methods known in the art. Briefly, the cDNA clone corresponding to the identified target-fungus specific antigen, or more generally any nucleic acid polymer encoding the target-fungus specific protein antigen, can be incorporated into an expression vector for recombinant production of the protein antigen, as discussed below.

The nucleic acid polymer can have the cDNA nucleotide sequence of the isolated cDNA clone. The nucleic acid polymer can, alternatively, have a mRNA nucleotide sequence corresponding to the cDNA sequence. Where the target fungus is *H. capsulatum*, the nucleic acid polymer preferably has the cDNA nucleotide sequence set forth as SEQ ID NO:2 or a mRNA nucleotide sequence corresponding to the sequence set forth as SEQ ID NO:2.

In an additional embodiment, the nucleic acid polymer can encode a fungus-specific protein antigen and have a nucleotide sequence which includes at least a portion of the nucleotide sequence of the isolated cDNA, the included portion being at least 15 base pairs in length. In a further embodiment, the nucleic acid polymer can be at least 15 base pairs in length and encode a fungus-specific protein antigen having an amino acid sequence which has a sequence identity or, alternatively, a homology of at least about 75%, more

preferably at least about 90%, even more preferably at least about 95% and most preferably at least about 98% relative to the amino acid sequence encoded by the isolated cDNA.

5 The above-disclosed nucleic acid polymer which encodes a fungus-specific protein antigen is preferably used to create a vector which is used, for example, to replicate or translate the nucleic acid polymer. Translation of the nucleic acid polymer is preferably
10 accomplished by an expression vector by methods known in the art. The expression vector can be, for example, a hybrid plasmid, a virus, or other nucleic-acid-polymer construct which is suitable for use in expressing the antigen in a eukaryotic or prokaryotic host-cell, in
15 vitro, according to methods known in the art. In the case of *H. capsulatum*, preferred expression vectors are λ gt11 and the pProEX™-1 protein expression system, which produces a fusion protein containing 6 histidines.

 A host cell can be transformed with the above-
20 disclosed vector for recombinant production of the target fungus-specific protein antigen. The host cell can be, for example, a bacterial host cell such as *E. coli*, a yeast cell, a mammalian cell, or any other suitable host cell in which the antigen can be expressed and from which
25 the antigen can be substantially isolated and purified.

 The isolated fungus-specific protein antigen can be utilized to produce an antibody specific for the antigen. The antigenic protein or fragment against which the antibody is raised and to which the antibody binds is
30 preferably substantially purified, and is further characterized as set forth above, with the various aspects defining the protein antigen to be considered both independently and in combination.

 The antibody may be a mono-specific antibody. The
35 monospecific antibody may be a monoclonal antibody produced, for example, by the method of Galfre et al.,

Nature 266:550 (1977). Alternatively, the monospecific antibody may be a recombinant antibody produced, for example, by the method of Lowman et al, Biochemistry 30:10832-10838 (1991).

5 The antibody can also be a polyclonal antibody. The polyclonal antibody can be prepared by immunizing a mammal such as a mouse or rabbit with the fungus-specific antigen and subsequently isolating the serum therefrom to obtain an antiserum that contains the polyclonal
10 antibodies. If the fungus is a pathogen of a vertebrate animal, such as *H. capsulatum*, polyclonal antibodies reactive to the specific antigen are generally produced in the serum of an infected animal. That serum may be collected and utilized as a polyclonal antiserum to the
15 fungus.

 The target fungus-specific antigen, and antibodies made to that specific antigen can be utilized in assays to determine the presence or absence, in a sample, of antigens or antibodies which are indicative of or
20 diagnostic for the target fungus.

 Any portion of the antigen which is specific for the fungus may be utilized for identifying the target fungus in a sample, and specific peptide sequences as small as five amino acids in length may be easily obtained by
25 methods known in the art. These specific fragments may, for example, be used alone or they may be engineered by methods known in the art to be part of a fusion protein, preferably comprising two domains, a first domain that includes at least a portion of the amino acid sequence
30 encoded by the nucleic acid polymer, the included portion being at least 5 amino acids in length, and a second domain that includes the amino acid sequence of another protein or polypeptide. In a preferred embodiment, the second domain includes the amino acid sequence of a
35 protein from the expression vector, such as β -galactosidase or other protein incorporated in an

expression system, which may facilitate expression and/or subsequent purification of the expressed antigen from the host-cell lysate.

5 In the case of a fungus disease of humans and other animals, the tests will preferably allow one to distinguish the fungal disease from other clinical conditions, especially from other fungal infections. Without being bound to a particular theory not specifically required in the claims, the target-fungus
10 specific antigens result from the above-disclosed method because the expressed proteins from the cDNA expression library do not contain carbohydrate moieties which would be present in fungal antigen preparations prepared by prior art methods. Prior art methods of immunizing
15 vertebrates with components of the target fungus generally failed to identify specific antigens because the immune system of the immunized vertebrate would mount an immune response to the antigenic carbohydrate moieties of the immunogen target fungus. However, the
20 carbohydrate moieties of the immunogen target fungus are often also present in the nontarget fungi, thus leading to cross-reactivities with the nontarget fungi. In particular, fungi which are closely related taxonomically, such as *H. capsulatum* and *B. dermatitidis*,
25 generally have more antigenic determinants in common than fungi which are less closely related, such as *H. capsulatum* and *Agaricus bisporus*, the common cultivated mushroom. As such, the present method is particularly suited for developing immunoassays for target fungi which
30 might be confused for closely related nontarget fungi.

In the preferred embodiment, a test for histoplasmosis developed with an antigen specific for *H. capsulatum* (as in the Example) allows a determination of the presence or absence of antibodies to *H. capsulatum*
35 which do not immunoreact with nontarget fungi present in the sample -- particularly *Coccidioides immitis*,

Blastomyces dermatiditis, and/or *Candida* species. Thus, the invention as applied to *H. capsulatum* provides diagnostic methods (i.e., assays) for determining whether a mammal has been infected with *H. capsulatum*. These
5 methods, combined with clinical observations and findings based on known and/or on later-developed techniques, facilitate diagnosis of histoplasmosis.

One embodiment of the assay method as applied to a target fungus is referred to herein as an antibody assay.

10 This method comprises detecting the presence or absence of antibodies to a target fungus-specific antigen in a sample obtained from a vertebrate. The presence or absence of the target fungus-specific antibodies are detected by contacting the sample with an antigen
15 specific to the target fungus and determining whether the sample contains antibodies that bind to the target fungus-specific antigen. The preferred antigen is further characterized as set forth above, with the various aspects defining the antigen to be considered
20 both independently and in combination. Exemplary antibody assays, discussed in more detail below, include precipitin-based immunoassays, indirect label-based immunoassays, direct label-based immunoassays and inhibition/competitive-type label-based immunoassays.

25 The presence of target fungus-specific antibodies in a sample obtained from the mammal is evidence of current and/or past exposure or infection with the target fungus. In an alternative embodiment, referred to herein as an antigen assay, the method comprises detecting the
30 presence or absence of antigens specific to the target fungus in a sample. The presence or absence of target fungus-specific antigens is detected by contacting the sample with an antibody capable of binding to a target fungus-specific antigen and determining whether the
35 antibody binds to the target fungus-specific antigen. The preferred target fungus-specific antibody is as set

forth above, with the various aspects defining the antibody to be considered both independently and in combination. The target fungus-specific antigen being detected is further characterized as set forth above,
5 with the various aspects defining the antigen to be considered both independently and in combination. Exemplary antigen assays, discussed in more detail below, include precipitin-based immunoassays, indirect label-based immunoassays, direct label-based immunoassays and
10 inhibition/competitive-type label-based immunoassays. The presence of antigens specific to the target fungus in a sample is evidence of the presence of the target fungus in the sample.

As applied to *H. capsulatum*, the detection of
15 antibodies which bind to the *H. capsulatum*-specific antigen in a sample from a mammal is evidence of past or current infection with *H. capsulatum*. Similarly, the detection of *H. capsulatum*-specific antigens in a sample from a mammal is strong evidence of current infection
20 with *H. capsulatum*.

The following additional concerns are applicable to either of the aforementioned antibody assay or antigen assay as applied to a target fungus such as *H. capsulatum*. The mammals from which a sample is obtained
25 are preferably humans, domestic livestock and/or pets which are suspected of being or known to be susceptible to fungal infection by the target fungus (e.g. *H. capsulatum*). The sample can be a blood sample, a plasma sample, a serum sample, a urine sample, a sputum sample,
30 a saliva sample or any other biological sample obtained from the mammal which is suspected of potentially having antibodies to the target fungus (e.g. *H. capsulatum*) or having target-fungus (e.g. *H. capsulatum*) antigens.

The sample can be pretreated prior to testing the
35 sample in the assay. Exemplary pretreatment steps can include concentrating the sample and/or eliminating

interfering substances (e.g. acid in urine or rheumatoid factors in serum). Other pretreatment steps will be apparent to a person of skill in the art. Moreover, additionally or alternatively to detecting whether
5 antigen-antibody binding occurs in either of the aforementioned general methods, the extent of such binding can be quantitatively determined using methods known in the art.

The antibody assays of the present invention can be
10 more specifically characterized according to a variety of formats set forth below and/or known in the art. One approach includes the use of precipitin-based immunoassays. For example, the presence or absence of the antibodies can be detected by layering a first
15 solution including the target fungus-specific antigen over the undiluted (i.e., neat) sample or over a second solution including the sample, the layered solution typically being formed in a container such as a test-tube, and observing the layered solution for the
20 formation or the lack of formation of a precipitate comprising bound antigen and antibody. The amount of target fungus-specific antigen in the first solution is preferably an amount which is necessary, on average, to form a precipitate with samples drawn from a vertebrate
25 known to contain antibodies to the target fungus. The steps of this approach can, alternatively, be repeated, in parallel or in series, using various amounts of the target fungus-specific antigen in the first solution, with the amount of antigen in the solution varying over a
30 range which includes an amount which is about, on average, necessary to form a precipitate with samples drawn from mammals known to have histoplasmosis. Precipitin-based immunoassays can also be carried out in gels such as agar or polyacrylamide gels or their
35 equivalents known in the art, by methods typically referred to as immunodiffusion, immunoelectrophoresis,

counterimmunoelectrophoresis and/or rocket electrophoresis, among others. For example, the presence or absence of the antibodies are detected by placing a first solution including the target fungus-specific antigen in a gel or in a well adjacent to a gel, placing the undiluted sample or a second solution including the sample, in a gel or in a well adjacent to a gel, allowing the target fungus-specific antigen and antibodies to diffuse in the gel, and observing the gel for the formation or the lack of formation of a precipitate comprising bound antigen and antibody. Turbidometric or nephelometric-type assay formats can also be employed. Precipitin-based immunoassays offer the advantage of not requiring a solid-phase matrix, and as such, may be suited for particular applications known in the art (e.g. automated systems).

Another approach for the antibody assay of the present invention includes the use of label-based assay techniques, including direct, indirect and/or inhibition/competitive radioimmunoassays, enzyme-linked immunoabsorbant assays (ELISA), immunofluorescent assays, immunochromatographic assays, and other techniques known in the art. For example, the presence or absence of the antibodies can be detected using an indirect label-based immunoassay by immobilizing the target fungus-specific antigen on a solid-phase, contacting the immobilized antigen with the undiluted sample or with a solution including the sample to allow any target fungus-specific antibody which may be present in the sample to specifically bind to the immobilized antigen, thereby forming a first immobilized complex which includes either solid-phase/target fungus-specific antigen or solid-phase/target fungus-specific antigen/antibody depending on whether the target fungus-specific antibody was present in the sample, washing the first immobilized complex to remove any unbound target fungus antibody

and/or other serum components, contacting the first immobilized complex with a detectable secondary antibody capable of binding to the target fungus-specific antibody, thereby forming a second immobilized complex which includes either solid-phase/target fungus-specific antigen or solid-phase/target fungus-specific antigen/antibody/secondary-antibody depending on whether target fungus antibody was present in the sample, washing the second immobilized complex to remove any unbound secondary antibody, and detecting the presence or absence of the secondary antibody on the second immobilized complex. The detectable secondary antibody can be labeled according to methods known in the art or later developed. For example, the secondary antibody can be a radiolabeled antibody (e.g. an antibody labeled with a gamma-emitting ^{125}I isotope) which is detected by radiographic methods or with instruments such as counters which measure the level of radioactivity present. The secondary antibody can also be an enzyme-conjugated antibody (e.g. an antibody conjugated with alkaline phosphatase, horseradish peroxidase, or other enzyme) which is detected by contacting the enzyme-conjugated antibody with a color-producing enzyme substrate. The secondary antibody can alternatively be tagged with biotin (or an equivalent) or with a fluorochrome (e.g. fluorescein and rhodamine) or a dye or other colored substance (e.g. colloidal gold) which can be detected visually or by known spectroscopic methods.

In another example of an indirect label-based immunoassay, the presence or absence of target fungus-specific antibodies can be detected using a Western blot format. This method is particularly advantageous in that it includes a step for separating the target fungus-specific antigen from other proteins in the sample in which it is present (e.g. for isolating recombinantly-produced target fungus-specific antigen present in a

host-cell lysate). This method includes electrophoretically separating a target fungus-specific protein antigen electrophoretically, transferring the separated protein antigen to a solid-phase membrane (e.g. a nitrocellulose or nylon membrane), contacting the solid-phase/target fungus-specific antigen complex with an undiluted sample or with a solution including the sample to allow any target fungus-specific antibody which may be present in the sample to bind to the antigen, and to form a first complex which includes either solid-phase/target fungus-specific antigen or solid-phase/target fungus-specific antigen/antibody, depending on whether antibody was present in the sample, washing the first complex to remove any unbound antibody, contacting the first complex with a detectable secondary antibody capable of binding to the solid phase-bound antibody, thereby forming a second immobilized complex which includes either solid-phase/target fungus-specific antigen or solid-phase/target fungus-specific antigen/antibody/secondary-antibody depending on whether target fungus-specific antibody was present in the sample, washing the second immobilized complex to remove any unbound secondary antibody, and detecting the presence or absence of the secondary antibody on the second immobilized complex. The detectable secondary antibody can, for example, be radiolabeled, enzyme-conjugated, tagged with a fluorochrome, or dyed as described above.

The presence or absence of target fungus-specific antibodies can, in another exemplary method, be detected using a direct label-based immunoassay. This method includes immobilizing a first anti-immunoglobulin antibody (e.g. IgG) capable of binding to the target fungus antibody being detected on a solid-phase (e.g. beads, membrane, matrix, etc.), contacting the immobilized anti-immunoglobulin antibody with an

undiluted sample or with a solution including the sample to form a first complex which includes either solid-phase/anti-immunoglobulin-antibody or solid-phase/anti-immunoglobulin-antibody/target fungus-specific antibody, depending on whether target fungus-specific antibody was present in the sample, washing the first complex, contacting the first complex with a labeled target fungus-specific antigen to allow any target fungus-specific antibody present in the first complex to bind to the target fungus-specific antigen and to form a second complex comprising either solid-phase/anti-immunoglobulin-antibody or solid-phase/anti-immunoglobulin-antibody/target fungus-specific antibody/target fungus-specific antigen, depending on whether target fungus-specific antibody was present in the sample, washing the second complex to remove any unbound labeled target fungus-specific antigen, and detecting whether the labeled target fungus-specific antigen is present or absent in the second complex. The target fungus-specific antigen can be labeled according to methods now known in the art or later developed, including, for example, being radiolabeled, enzyme-conjugated, tagged with a fluorochrome, dyed or otherwise associated with a colored material, as described above.

25 The presence or absence of target fungus-specific antibodies can, in a further exemplary method, be detected using an inhibition/competitive label-based immunoassays. This method includes establishing a baseline reading for a control assay by immobilizing a target fungus-specific antigen on a solid-phase, contacting the immobilized target fungus-specific antigen with a detectable (e.g. labeled) target fungus-specific antibody to form a control complex including solid-phase/target fungus-specific-antibody/detectable target fungus-specific antibody, washing the control complex to remove any unbound detectable target fungus-specific

antibody therefrom, and detecting the baseline level of target fungus-specific antibody bound to the immobilized target fungus-specific antigen on the control complex. The method further includes, in a separate, independent test assay, immobilizing a target fungus-specific antigen on a solid-phase, contacting the immobilized target fungus-specific antigen with both (1) a detectable (e.g. labeled) target fungus-specific antibody and (2) an undiluted sample or with a solution including the sample to allow any target fungus-specific antibody which may be present in the sample to bind to at least some of the immobilized target fungus-specific antigen and to thereby form a test complex in which at least some of the bound detectable target fungus-specific antibody may have been competitively inhibited from binding to the immobilized target fungus-specific antigen, depending on whether target fungus-specific antibody was present in the sample, washing the test complex to remove any unbound target fungus-specific antibody, detecting the level of detectable-target fungus-specific antibody bound to the test complex, and comparing the level of detectable-target fungus-specific antibody bound to the test complex to the baseline level of detectable target fungus-specific antibody bound to the control complex, a decrease in such level indicating the presence of target fungus-specific antibody in the sample. The detectable target fungus-specific antibody can, for example, be radiolabeled, enzyme-conjugated, tagged with a fluorochrome, dyed or otherwise associated with a colored material as described above.

The approaches set forth above for determining the presence or absence of antibodies to target fungus-specific antibody in a sample are to be considered exemplary and non-limiting of the many formats known in the art by which a sample suspected of including antibodies is contacted with an antigen and the presence

or absence and/or quantitative extent of antigen-antibody binding is determined. Moreover, the exact sequence of steps is not narrowly critical and can be varied as is appropriate in the art. Certain steps may be omitted
5 altogether and/or combined with other steps. For example, the sample and labeled antigen can, in some assay formats, be added together. As another example, assays may not require a washing step to remove unbound antibodies. Assays such as immunochromatographic assays
10 where reactants flow across and/or through the solid phase are exemplary. Certain additional steps may also be added, in series and/or in parallel combination, to the aforementioned steps, as appropriate in the art. For example, the assays can optionally include one or more
15 blocking steps or proteins or detergents in the diluent to decrease the non-specific binding of antibodies, primary or secondary, to the solid-phase. The assays of the invention can also be automated, with appropriate modifications to the described steps. All of the above
20 antibody assays are effective in detecting target fungus-specific antibodies for any fungus, including *H. capsulatum*, which is capable of eliciting an antibody response in a vertebrate.

The antigen assays of the present invention are
25 useful in any situation where a determination of the presence or absence of a target fungus is desired. Examples include the determination of the presence of a target fungus in an animal or plant suspected of being infected with the target fungus, in a food or feed
30 suspected of being contaminated with the target fungus, in inorganic materials such as soil or air for the determination of the presence of an allergenic or pathogenic target fungus, and for the identification of a specific target fungus where the identity of the fungus
35 is unknown.

The antigen assays of the present invention can be more specifically characterized according to a variety of formats set forth below and/or known in the art. One approach includes the use of precipitin-based

5 immunoassays. For example, the presence or absence of the target fungus-specific antigens in the sample can be detected by layering a first solution including the target fungus-specific antibody over the undiluted sample or over a second solution including the sample, the

10 layered solution typically being formed in a container such as a test-tube, and observing the layered solution for the formation or the lack of formation of a precipitate comprising bound antigen and antibody. The amount of target fungus-specific antibody in the first

15 solution is preferably an amount which is necessary, on average, to form a precipitate with samples previously known to comprise the target fungus. The steps of this approach can, alternatively, be repeated, in parallel or in series, using various amounts of the target fungus-

20 specific antibody in the first solution, with the amount of antibody in the solution varying over a range which includes an amount which is about, on average, necessary to form a precipitate with samples previously known to contain the target fungus-specific antigen. Precipitin-

25 based immunoassays can also be carried out in gels such as agar or polyacrylamide gels or their equivalents known in the art, by methods typically referred to as immunodiffusion, immunoelectrophoresis, counterimmunoelectrophoresis and/or rocket

30 electrophoresis, among others. For example, the presence or absence of the antigens are detected by placing a first solution including the target fungus-specific antibody in a gel or in a well adjacent to a gel, placing the undiluted sample or a second solution including the

35 sample, in a gel or in a well adjacent to a gel, allowing the target fungus-specific antibody and antigens to

diffuse within the gel and observing the gel for the formation or the lack of formation of a precipitate comprising bound antigen and antibody.

Another approach for the antigen assay of the present invention includes the use of label-based assay techniques, including direct, indirect and/or inhibition/competitive radioimmunoassays, enzyme-linked immunoabsorbant assays (ELISA), immunofluorescent assays, immunochromatographic assays, and other techniques known in the art. For example, the presence or absence of the antigens can be detected in a direct sandwich-type format by immobilizing target fungus-specific antibody on a solid-phase, contacting the immobilized antibody with an undiluted sample or with a solution including the sample to allow any target fungus-specific antigen which may be present in the sample to bind to the immobilized antibody, thereby forming a first immobilized complex which includes either solid-phase/target fungus-specific antibody or solid-phase/target fungus-specific antibody/target fungus-specific antigen, depending on whether the target fungus-specific antigen was present in the sample, washing the first immobilized complex to remove any unbound target fungus-specific antigen, contacting the complex with a detectable secondary antibody capable of binding to a different epitope on the target fungus-specific antigen, thereby forming a second immobilized complex which includes either solid-phase/target fungus-specific antibody or solid-phase/target fungus-specific antibody/target fungus-specific antigen/secondary-antibody, depending on whether target fungus-specific antigen was present in the sample, washing the second immobilized complex to remove any unbound secondary antibody, and detecting the presence or absence of the secondary antibody on the second immobilized complex. The secondary antibody can, for

example, be radiolabeled, enzyme-conjugated, tagged with a fluorochrome or dyed as described above.

In another example of an indirect label-based immunoassay, the presence or absence of target fungus-specific antigen can be detected using a Western blot format. This method includes electrophoretically separating proteins contained in the sample in a gel (e.g. such as a polyacrylamide gel), electrophoretically transferring the separated proteins to a solid-phase membrane (e.g. a nitrocellulose membrane), contacting the separated proteins with an unlabeled target fungus-specific antibody to allow any target fungus-specific antigen which may have been present in the sample to bind to the antibody and form a first complex which includes either solid-phase/target fungus-specific antigen or solid-phase/target fungus-specific antigen/target fungus-specific antibody, depending on whether target fungus-specific antigen was present in the sample, washing the first complex to remove unbound target fungus-specific antibody, contacting the first complex with a detectable secondary antibody to form second complex which includes either solid-phase/target fungus-specific antigen or solid-phase/target fungus-specific antigen/target fungus-specific antibody/secondary-antibody, depending on whether target fungus-specific antigen was present in the sample, and detecting the presence or absence of the secondary antibody bound to the antigen in the second complex. The secondary antibody can, for example, be radiolabeled, enzyme-conjugated, tagged with biotin or an equivalent thereto, a fluorochrome, dyed or otherwise associated with a colored material as described above.

In an exemplary direct Western blot immunoassay, the presence or absence of the antigens in the sample can be detected using a method which includes electrophoretically separating proteins contained in the sample in a gel (e.g. such as a polyacrylamide gel),

transferring the separated proteins to a solid-phase membrane (e.g. a nitrocellulose or nylon membrane), contacting the transferred proteins with a detectable target fungus-specific antibody to allow any target
5 fungus-specific antigen which may have been present in the sample to bind to the target fungus-specific antibody and form a complex which includes either gel/target fungus-specific antigen or gel/target fungus-specific antigen/target fungus-specific antibody, washing any
10 unbound target fungus-specific antibody away from the gel and detecting the presence or absence of labeled target fungus-specific antibody bound to the antigen in the gel. The target fungus-specific antibody can, for example, be radiolabeled, enzyme-conjugated, tagged with a
15 fluorochrome or dyed, as described above.

Alternatively, the presence or absence of the antigens in a sample can be detected in an inhibition/competitive-type format by mixing a solution including a detectable (e.g. labeled) target fungus-
20 specific antibody with the undiluted sample or with a solution including the sample to allow any target fungus-specific antigen which may be present in the sample to bind with the detectable target fungus-specific antibody and to form a test solution which includes either unbound
25 detectable target fungus-specific antibody or a detectable target fungus-specific antibody/target fungus-specific antigen complex depending on whether target fungus-specific antigen was present in the sample. The method further includes immobilizing a target fungus-
30 specific antigen on a solid-phase, contacting the immobilized target fungus-specific antigen with the test solution to allow any unbound detectable target fungus-specific antibody present in the test solution to bind with the immobilized target fungus-specific antigen and
35 form an immobilized complex including solid-phase/target fungus-specific antigen or solid-phase/target fungus-

specific antigen/detectable target fungus-specific antibody depending on whether target fungus-specific antigen was present in the sample, washing the solid-phase to remove any unbound target fungus-specific antibody, and measuring the presence or absence of the detectable target fungus-specific antibody on the immobilized complex. The detectable antibody can be radiolabeled, enzyme-conjugated, tagged with a fluorochrome or dyed, as described above. In an alternative variation on this type of format, an antigen assay can include immobilizing a target fungus-specific antibody on a solid-phase, contacting the immobilized antibody with both (1) a detectable (e.g. labeled) target fungus-specific antigen and (2) an undiluted sample or a solution including the sample to allow any target fungus-specific antigen which may be present in the sample to bind to at least some of the immobilized target fungus-specific antibody and to thereby form a test complex in which at least some of the detectable target fungus-specific antigen may have been competitively inhibited from binding to the immobilized target fungus-specific antibody, depending on whether target fungus-specific antigen was present in the sample, washing the test complex to remove any unbound target fungus-specific antigen, and detecting the level of detectable target fungus-specific antigen bound to the test complex. If desired, the level of detectable target fungus-specific antigen bound to the test complex can be compared to a baseline level of detectable target fungus-specific antigen bound to a control complex, with a decrease in such level indicating the presence of target fungus-specific antigen in the sample. The detectable target fungus-specific antigen can, for example, be radiolabeled, enzyme-conjugated, tagged with biotin or an equivalent thereto, a fluorochrome, dyed or otherwise associated with a colored material as described above.

The approaches set forth above for determining the presence or absence of target fungus-specific antigens in a sample are to be considered exemplary and non-limiting of the many formats known in the art by which a sample suspected of including antigens is contacted with an antibody and the presence or absence and/or quantitative extent of antigen-antibody binding is determined. Moreover, the exact sequence of steps is not narrowly critical and can be varied as is appropriate in the art. Certain steps may be omitted altogether and/or combined with other steps. For example, the sample and labeled antigen can, in some assay formats, be added together. As another example, assays may not require a washing step to remove unbound antibodies. Assays such as immunochromatographic assays where reactants flow across and/or through the solid phase are exemplary. Certain additional steps may also be added, in series and/or in parallel combination, to the aforementioned steps, as appropriate in the art. For example, the assays can optionally include one or more blocking steps to decrease the non-specific binding of antibodies, primary or secondary, to the solid-phase. The assays of the invention can also be automated, with appropriate modifications to the described steps. All of the above antigen assays are effective in detecting target fungus-specific antigens for any fungus, including *H. capsulatum*.

Kits are provided which are suitable for use in performing the aforementioned assay methods to facilitate diagnosis of histoplasmosis in humans and other mammals. In one embodiment, an assay kit of the present invention can include labeled and/or unlabeled target fungus-specific antigen, as described above, in quantities sufficient to carry out the assays of the present invention. In another embodiment, an assay kit can include labeled and/or unlabeled antibodies to an target

fungus-specific antigen, as described above, in quantities sufficient to carry out the assays of the present invention. In a further embodiment, an assay kit of the present invention can include both labeled and/or
5 unlabeled target fungus-specific antigen and labeled and/or unlabeled antibody thereto, each as described above, in quantities sufficient to carry out the assays of the present invention. In any of the aforementioned embodiments, an assay kit can also further comprise known
10 positive and/or negative control samples, other reagents useful in carrying out the assays of the present invention (e.g. radiolabeled secondary antibodies and/or enzyme-conjugated secondary antibodies along with the corresponding color-producing enzyme substrate
15 therefore), and instructions for carrying out the assay methods. Kits as provided above may be utilized for any target fungus, including *H. capsulatum*.

The following example illustrates the invention, but is not to be taken as limiting the various aspects of the
20 invention so illustrated.

Example

MOLECULAR CLONING AND CHARACTERIZATION OF A RECOMBINANT *HISTOPLASMA CAPSULATUM* ANTIGEN FOR ANTIBODY DIAGNOSIS OF HUMAN HISTOPLASMOSIS

25 MATERIALS AND METHODS

Fungi and culture conditions. *H. capsulatum* G217B, a North American isolate, was obtained from the American Type Culture Collection (ATCC #26032, Rockville, MD). Mycelial-phase organisms were cultured in a shaking water
30 bath at 25°C in broth containing 2% glucose and 1% yeast extract. Yeast-phase organisms were grown at 37°C in HMM broth (Gibco-BRL, Gaithersburg, MD) supplemented with 18.2 g of glucose, 1.0 g of glutamic acid (per liter), adjusted to pH 7.5 (17).

Human and animal sera. Human sera were obtained from patients with well-documented histoplasmosis (n=18), coccidioidomycosis (n=12), and candidiasis (n=5). Coccidioidomycosis sera were generously provided by Dr. Demothenes Pappagianis, University of California School of Medicine (Davis, CA). The histoplasmosis sera were obtained from patients with acute and chronic disease and from patients with disseminated infections (with positive bone marrow and/or blood cultures) associated with AIDS.

5 The laboratory diagnosis of histoplasmosis infections was based on culture and biopsy results and/or serology tests (immunodiffusion and complement fixation with yeast and mycelial antigens). Blastomycosis sera from humans (n=5) and dogs (n=6) with documented clinical infections

10 and sera from rabbits immunized with *Blastomyces dermatitidis* antigens or whole yeast cells (n = 3) were a gift from Dr. Gene Scalerone (Idaho State College, Pocatello, ID).

Control human sera were obtained from healthy residents of St. Louis, MO. A histoplasmosis serum pool was prepared with sera (n=12) from patients with proven histoplasmosis.

20

Isolation of *H. capsulatum* DNA. Genomic DNA from yeast cells was isolated essentially as previously described (17,34). Briefly, yeast cells were pelleted and resuspended in TE buffer (10 mM Tris, pH 8.0; 1 mM EDTA). SDS was added to 1% final concentration. DNA was extracted using phenol-chloroform, ethanol precipitated, and washed with 70% ethanol.

25

Mouse sera. Antibodies to yeast antigen or to a histidine fusion protein of the recombinant clone GH17 (GH17-his, see below) were produced in 6-week-old female BALB/c mice by foot-pad injection of 10 µg of yeast antigen or purified GH17-his in FCA followed by a second injection of antigen in IFA 4 weeks later. Sera were collected 1 week after the booster immunization.

30

35

Yeast antigen. Yeast cells were suspended in 0.01M Tris buffer (pH 8.3) containing protease inhibitors (1 mM phenyl methyl sulfonyl fluoride, 1 mM EDTA, 25 µg/ml N-tosyl-L-phenylalanine chloromethyl ketone, and 25 µg/ml N-a-p-tosyl-L-lysine chloromethyl ketone (all from Sigma Chemical Company, St. Louis, MO). The yeast homogenate was rocked at 4°C overnight and centrifuged at 15,000 x g for 10 min. The protein concentration in the supernatant was measured with a commercial kit (BCA; Pierce Chemical Co., Rockford, IL).

Screening of a gene expression library and selection of recombinant clones. A λgt11 cDNA library was custom-synthesized (Clontech Lab. Inc., Palo Alto, CA) using Poly(A)⁺ mRNA derived from the mycelial stage of the G217B strain of *H. capsulatum*. This library has a recombinant frequency of over 90% after amplification. The DNA insert size range is 0.6-4.5 kb with an average size of 1.6 kb. The library was immunoscreened to identify *H. capsulatum*-specific clones essentially as previously described (5,6). Clones that were reactive with antibodies in the histoplasmosis serum pool but not reactive with a normal human serum pool were selected and purified by repeated cycles of immunoselection. The reactivity of serum pools to fusion proteins expressed by purified recombinant phage was studied by plaque-dot immunoblot analysis as previously described (5). PCR was employed to amplify the cDNA inserts of selected recombinant λgt11 clones with the GenAmp DNA amplification kit (Perkin Elmer-Cetus, Norwalk, CT) as previously described (31). DNA dot hybridization was performed using peroxidase-labeled DNA fragments (14) to assess homology between the selected clones.

Southern blot analysis and DNA sequencing. *H. capsulatum* genomic DNA (5 µg) was cut with selected restriction endonuclease enzymes. Digestion products were electrophoresed in a 1% agarose gel and transferred

to Hybond-N+ nylon transfer membrane (Amersham, Arlington Heights, IL) by standard techniques, and blots were probed with labeled cDNA insert of GH17 (26).

5 λ gt11 DNA purified from GH17 was digested with *EcoRI* and ligated into pBluescript II SK- (Stratagene Cloning Systems, La Jolla, CA) by standard methods (26), and plasmid DNA was prepared for DNA sequencing. The dideoxynucleotide chain termination method (32) was used for double stranded DNA sequencing using the TaqTrack Sequencing System (Promega Corporation, Madison, WI) with T3 and T7 pBluescript primers and with synthetic oligonucleotides.

10 The PC/GENE DNA Sequence Analysis Software (Intelligenetics, Mountain View, CA) and the BLAST Program (NCBI, NLM, NIH, Bethesda, MD) were used to analyze nucleotide and deduced amino acid sequences and to determine sequence homologies with previously reported sequences in the GenBank™ data base.

20 **Expression and purification of GH17 in the pPROEX™-1 Protein Expression system.** The cDNA insert of the recombinant clone GH17 was subcloned directionally into the plasmid expression vector pPROEX™-1 (Gibco-BRL) to produce a fusion protein containing 6 histidines. GH17 fusion protein (GH17-his) was purified from bacterial lysates by continuous-elution electrophoresis using a BioRad Prep Cell (BioRad Laboratories, Hercules, CA). Briefly, a 10-ml overnight culture of *Escherichia coli* (BL21 strain) cells containing the recombinant plasmid GH17 was inoculated into 700 ml NZCYM medium (Gibco-BRL) containing 50 μ g ampicillin per ml (Sigma). Cultures were grown at 37°C with shaking to OD₆₀₀ of 1.0. IPTG (final concentration, 0.3 mM) was then added, and the culture was grown for an additional 5 h, after which the cells were pelleted and resuspended in 1:50 v/v of lysis buffer (10 mM Na₂HPO₄, 30 mM NaCl, 0.25% Tween 20, 10 mM EDTA, 10 mM EGTA, pH 7.0). The cells were frozen at -20°C overnight. Cells were thawed in cold water and lysed by

mild sonication. Cellular debris was removed by centrifugation at 10,000 x g for 15 min. A 12% polyacrylamide gel was poured per the manufacturer's protocol for the BioRad Model 491 Prep Cell. Ten ml of sample in 1:1 loading buffer (0.0625M Tris-HCl, pH 6.8, 10% glycerol, 0.025% bromphenol blue) was loaded and the gel was run for 8 hrs at 12W constant power. Three ml fractions were collected and run on 12% SDS-PAGE minigels (21). Western blots (35) were performed with the histoplasmosis human serum pool to identify fractions that contained the GH17 fusion protein. Three consecutive fractions containing the band of interest were selected, pooled, and dialyzed versus PBS, pH 7.2. The dialyzed protein was concentrated with a membrane concentrator (Centriplus,TM Amicon, Beverly, MA) and the protein concentration was measured with a commercial kit (BCA; Pierce Chemical Co.)

Immunoblot analysis of recombinant fusion proteins.

E. coli Y1090 was infected at high density with recombinant phage on a thin layer of agarose over LB-agar to achieve confluent lysis, and synthesis of fusion proteins encoded by cDNA inserts was induced with IPTG-impregnated filters. The agarose layer containing bacterial lysate and fusion protein was then gently scrapped off and dissolved in SDS-PAGE sample buffer. SDS-PAGE was performed as described by Laemmli (21) at 135 V in 8% reducing gels. After SDS-PAGE, proteins were transferred electrophoretically (35) to nitrocellulose membranes. Membranes were then incubated in monoclonal antibody to β -galactosidase (Promega Biotech, Madison, WI) or in canine or human sera diluted 1:500 in PBS/T for 3 h at 37°C. Membranes were washed in PBS/T and incubated with alkaline phosphatase conjugated goat anti-mouse, anti-dog or anti-human IgG (Promega) for 1 h at 37°C. After washing, membranes were developed with NBT/BCIP.

Immunoblot analysis was carried out with *H. capsulatum* yeast extract to identify the native

antigen(s) that correspond to the recombinant clone GH17. Yeast extract was separated by SDS-PAGE on 5-25% gradient slab gels and processed as described above with mouse antibody to GH17-his.

5 RESULTS

Selection of λ gt11 clones that express *H. capsulatum*-specific antigens. Approximately, 500,000 phage plaques from an *H. capsulatum*-mycelia phase cDNA expression library were immunoscreened with a
10 histoplasmosis serum pool and a normal control serum pool made from sera obtained from healthy residents of St. Louis who had no history of histoplasmosis. Twenty clones selected in the initial screen were rescreened with individual histoplasmosis sera. Eight highly
15 immunoreactive clones were identified. These were again tested by plaque-dot immunoblots with sera from patients with other non-*H. capsulatum* fungal infections, including *C. immitis*, *B. dermatitidis*, and *Candida* sp. Four clones that were reactive with antibodies in sera from
20 histoplasmosis patients and not reactive with antibodies from patients with other fungal infections were selected for further study. DNA dot hybridization studies showed that all four clones hybridized to each other even under high stringency conditions (data not shown). The four
25 clones designated as GH2, GH17, GH22 and GH23 produced a similar size β -galactosidase fusion protein with an apparent M_r of 140,000 vs. 116 kDa for unfused β -galactosidase (data not shown).

Molecular characterization of recombinant
30 ***Histoplasma* clones.** The cDNA inserts of clones GH2, 17 and 22 were sequenced. All three clones contained identical 5' ends and an identical 633 bp open reading frame (ORF). That ORF is disclosed herein as SEQ ID NO:2. The three clones had variable amounts of
35 untranslated DNA at the 3' ends (GH2- 260 bp; GH17- 142

bp; and GH22-166 bp). The complete nucleotide sequence of GH17 (GenBank™ Accession number U27588) is disclosed herein as SEQ ID NO:1. The deduced amino acid sequence of the translated protein is disclosed herein as SEQ ID NO:3. The presumed initiation codon 36 bp downstream from the 5' end is the first ATG in the ORF. The sequence also has a purine (adenine) in the -3 position (Kozak's rule), a prerequisite for an initiation codon (19). The initiation codon is followed by a hydrophobic sequence (predicted by hydropathy analysis, Fig. 2) which is consistent with a signal peptide sequence. Two potential signal peptidase cleavage sites were identified by the method of von Heijne (37) which predicts cleavage after residues 20 and 24. The sequence also contains a predicted transmembrane helix from amino acid 2 to 28 (28). The 3' non-coding region has a poly (A) tail of 14 bp. The ORF codes for a protein of 211 amino acids with a predicted size of 23.5 kDa and a calculated pI of 4.15. There are three potential N-glycosylation sites in the predicted amino acid sequence; these are located in the hydrophilic domains of the protein (boxed areas, Fig. 1). The GH17 sequence does not exhibit significant similarity to any proteins present in GenBank/EMBL sequence databases except for the similarity of the threonine-rich region to other threonine rich sequences such as cellulase of *Caldocellum saccharolyticum* (25), *Xenopus laevis* integumentary mucin (12), and a *Leishmania* surface antigen (27) (Fig. 2).

Southern blot analysis was performed to identify genomic fragments carrying the gene(s) encoding the recombinant clone GH17. When DNA was cut with *EcoRI* and *PstI* and probed with labeled cDNA insert of GH17, bands were detected at 4.9 kb and 5.5 kb, respectively (Fig. 3). The probe hybridized to two bands (8.5 kb and 5.0 kb) in *SacI* digested DNA. However, recombinant clone GH17 has an internal *SacI* site. These results suggest a single location in the *H. capsulatum* genome for GH17.

Sensitivity and specificity of IgG antibodies to recombinant *H. capsulatum* proteins. Immunoreactivity of recombinant *H. capsulatum* proteins produced by clones GH2, 17, 22, 23 was assessed by Western blot with sera from patients with a variety of fungal infections. Most sera from histoplasmosis patients had easily visible antibody reactivity with all 4 recombinant proteins (Table 1, Fig. 4A). The sensitivity of Western blot with these clones for histoplasmosis sera ranged from 89-100% (Table 1, Fig. 4A). None of these clones was recognized by sera from humans and animals infected with other fungi (Fig. 4B).

TABLE I. Sensitivity^a and Specificity of Immunoblot with Recombinant *H. capsulatum* Clones

		Clones			
5	Serum Source	GH2	GH17	GH22	GH23
	Histoplasmosis				
	Human	18/18 ^b	18/18	16/18	16/18
10	Blstomycosis				
	Dog	0/6	0/6	0/6	0/6
	Rabbit	0/3	0/3	0/3	0/3
	Human	0/5	0/5	0/5	0/5
	Coccidioidomycosis				
15	Human	0/12	0/12	0/12	0/12
	Candidiasis				
	Human	0/5	0/5	0/5	0/5
	Uninfected Controls				
	Human	0/12	0/12	0/12	0/12
20					

^aImmunoreactivity was assessed by immunoblot with β -galactosidase fusion proteins.

^bNo. of sera reactive/no. of sera tested.

Expression of GH17 in pPROEX™-1 expression vector.

The cDNA insert of GH17 was expressed as histidine fusion in the pPROEX™ -1 protein expression system. Plasmid pPROEX-1 consists of a Trc promotor for high level
5 expression in *E. coli*, a prokaryotic ribosome binding site, and a 6X His affinity tag for ease of purification. A fusion protein with an apparent size of 32 kDa was evident by SDS-PAGE and immunoblot (Fig. 5A). GH17-his failed to bind to a metal affinity column. Therefore,
10 the fusion protein was purified from bacterial lysates by continuous-elution electrophoresis using a BioRad PrepCell. Western blots were performed to select fractions of interest by immunoblotting with a human histoplasmosis serum pool (Fig. 5B). Three consecutive
15 fractions containing the band of interest were selected, pooled and dialyzed. This yielded a total of 500 µg of purified protein from approximately 700 ml of bacterial culture.

Pilot studies were carried out to test the purified
20 GH17-his protein in an ELISA format (data not shown). Unfortunately, ELISA based on the GH17-his protein was less sensitive and specific than the recombinant immunoblot assay with the GH17-β-galactosidase fusion protein. This lowered specificity and sensitivity is
25 believed to be due to cross-reactivity to the polyhistidine component of the GH17-his protein.

Immunoblot analysis of mouse antibodies to recombinant antigen. Sera from mice immunized with

GH17-his bound to a 60 kDa native *H. capsulatum* yeast antigen by Western blot (Fig. 6). This antigen was not recognized by pre-immune mouse sera.

DISCUSSION

5 The experiments of this Example demonstrate that *H. capsulatum*-specific antigens can be identified, cloned, characterized, and produced using recombinant DNA methodologies and other methods, as described. A recombinant *H. capsulatum* antigen was shown to have
10 highly specific and sensitive immunodiagnostic potential.

Recombinant clones that expressed *H. capsulatum*-specific antigens were identified by several cycles of differential immunoscreening, and the most immunoreactive and specific clone (GH17) was selected for more detailed
15 studies. GH17 codes for the most promising recombinant diagnostic antigen for histoplasmosis that has been identified to date. GH17 codes for a protein that corresponds to a 60 kDa native *H. capsulatum* antigen. There are three potential *N*-glycosylation sites [Asn-
20 Asn/Lys-Thr] in the predicted amino acid sequence of GH17 (boxed areas, Fig. 1). Glycosylation at these sites could account for the difference between the predicted polypeptide mass of 23.5 kDa and the observed size of the native yeast protein recognized by the mouse antibodies
25 to GH17 histidine fusion protein (60 kDa).

The protein encoded by GH17 is highly antigenic in humans with histoplasmosis. Chou-Fasman predictions

based on the deduced amino acid sequence of GH17 (7) indicate that the protein is rich in potential B cell epitopes. These predictions are based principally on the hydrophilic character and accessibility of highly charged and exposed polar residues that comprise the turns and alpha helices within the predicted GH17 protein (13,20). Our results with human sera are consistent with these predictions. GH17 produced a 140 kDa fusion protein that was recognized in Western blots by 18 of 18 sera from patients with histoplasmosis.

In contrast to previous serological work with *H. capsulatum* (15, 16, 36, 40, 41) the GH17 recombinant immunoblot assay appears to have excellent specificity for histoplasmosis.

15

As shown in the Example, the present invention provides a method to isolate specific fungal antigens. In particular, the present invention offers significant advantages over prior art fungal antigens, antibodies and diagnostic methods employing the same. The specificity of the present target fungus antigens and antibodies make them particularly advantageous for reliable determination of the presence of the target fungus or antibodies which are specific to the target fungus. As applied to target fungi which are pathogens of vertebrates, such as *H. capsulatum*, use of antigens and antibodies of the present invention are useful for providing reliable evidence of

present or past infection with *H. capsulatum*. Other features, objects and advantages of the present invention will be apparent to those skilled in the art. The explanations and illustrations presented herein are intended to acquaint others skilled in the art with the invention, its principles, and its practical application. Those skilled in the art may adapt and apply the invention in its numerous forms, as may be best suited to the requirements of a particular use. Accordingly, the specific embodiments of the present invention as set forth are not intended as being exhaustive or limiting of the invention.

REFERENCES

1. **Ajello, J.** 1971. Coccidioidomycosis and histoplasmosis: a review of their epidemiology and geographical distribution. *Mycopathol. Appl.* 45:221-230.
2. **Bauman, D. S., and C. D. Smith.** 1975. Comparison of immunodiffusion and complement fixation tests in the diagnosis of histoplasmosis. *J. Clin. Microbiol.* 2:77-80.
3. **Buechner, H. A., J. H. Seabury, and C. C. Campbe** 11. 1973. The current status of serologic, immunologic, and skin tests in the diagnosis of pulmonary mycoses. *Chest* 63:259-270.
4. **Chandler, J.W., T. K. Smith, and W. M. Newberry.** 1969. Immunology of mycoses. II. Characterization

- of the immunoglobulin and antibody responses in histoplasmosis. J. Infect. Dis. 119:247-254.
5. Chandrashekar, R., K. Masood, R. M. Alvarez, A. F. Ogunrinade, R. Lujan, F. Richards, and G. J. Weil. 1991. Molecular cloning and characterization of recombinant parasite antigens for immunodiagnosis of onchocerciasis. J. Clin. Invest. 8:1460-1466.
6. Chandrashekar, R., K. C. Curtis, R. M. Ramzy, F. Liftis, B. W. Li, and G. J. Weil. 1994. Molecular cloning of *Brugia malayi* antigens for diagnosis of lymphatic filariasis. Mol. Biochem. Parasitol. 64:261-271.
7. Chou, P. Y., and G. Fasman. 1978. Prediction of the secondary structure of proteins from their amino acid sequence. Adv. Enzymol. Relat. Areas Mol. Biol. 47:145-147.
8. Edwards, P. Q., and E. L. Billings. 1971. World-wide pattern of skin sensitivity to histoplasmin. Am. J. Trop. Med. Hyg. 20:288-319.
9. George, R. B., R. S. Lambert, M. J. Bruce, T. W. Pickering, and R. M. Wolcott. 1981. Radioimmunoassay: a sensitive screening test for histoplasmosis and blastomycosis. Am. Rev. Resp. Dis. 124:407-410.
10. Goodwin, Jr., R., and R. M. Prez. 1978. Histoplasmosis. Am. Rev. Respir. Dis. 117:929-955.

11. **Goodwin, R. A., Jr., and R. M. Des Perez.** 1979.
Histoplasmosis: State of the art. Am. Rev. Resp.
Dis. 119:247-254.
12. **Hauser, F. and W. Hoffman.** 1992. P-domains as
5 shuffled cysteine-rich modules in integumentary
mucin C.1 (FIM-C.1) from *Xenopus laevis*.
Polydispersity and genetic polymorphism. J. Biol.
Chem. 267:24620-24624.
13. **Hopp, T. P.** 1986. Methods for identifying antigenic
10 determinants and other interaction sites. J.
Immunol. Methods. 88:1-18.
14. **Kafatos, F. C., C. W. Jones, and A. Efstratiadis.**
1979. Determination of nucleic acid sequence
homologies by a dot hybridization procedure.
15 Nucleic Acids Res. 7:1541-1552.
15. **Kaufman L., and E. Reiss.** 1986. Serodiagnosis of
fungal diseases. p 446-466. In Rose, N.R., H.
Friedman, and J. L. Fahey. Manual of Clinical
Laboratory Immunology. 3rd edition. American Society
20 for Microbiology, Washington, D.C.
16. **Kaufman, L.** 1992. Laboratory methods for the
diagnosis and confirmation of systemic mycoses.
Clin. Infect. Dis. 14:S23-S29.
17. **Keath, E. J., A. A. Painter, G. S. Kobayashi, and G.**
25 **Medoff.** 1989. Variable expression of a yeast-
phase-specific gene in *Histoplasma capsulatum*
strains differing in thermotolerance and virulence.
Infect. Immun. 57:1384-1390.

18. King, K. 1982. Histoplasmosis in Australia. Aust. Med. J. 2:550-551.
19. Kozak, M. 1986. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell 44:283-292.
20. Kyte, J., and R. F. Doolittle. 1982. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157:105-132.
21. Laemmli, U. K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
22. Lambert, R. S., and R. B. George. 1987. Evaluation of enzyme immunoassay as a rapid screening test for histoplasmosis and blastomycosis. Am. Rev. Resp. Dis. 136:316-319.
23. Lobos, E., N. Weiss, M. Karam, H. R. Taylor, E. A. Ottesen, and T. B. Nutman. 1991. An immunogenic *Onchocerca volvulus* antigen: A specific and early marker of infection. Science 251:1603-1605.
24. Lustigman, S., B. Brotman, T. Huima, and A. M. Prince. 1991. Characterization of an *Onchocerca volvulus* cDNA clone encoding a genus-specific antigen present in infective larvae and adult worms. Mol. Biochem. Parasitol. 45:65-76.
25. Luthi, E., Jasmat, N. B., R. A. Grayling, D. R. Love, and P. L. Bergquist. 1991. Cloning, sequence analysis, and expression in *Escherichia coli* of a

gene coding for a beta-mannose from the extremely thermophilic bacterium *Caldocellum saccharolyticum*. Appl. Environ. Microbiol. 57:694-700.

26. Maniatis, T. E., F. Fritsch, and J. Sambrook. 1982. Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
27. Murray, P. J. and T. W. Spithill. 1991. Variants of a *Leishmania* surface antigen derived from a multigenic family. J. Biol. Chem. 266:24477-24484.
28. Rao, M. J. K., and Argos, P. 1986. A conformational preference parameter to predict helices in integral membrane proteins. Biochem. Biophys. Acta. 869:197-214.
29. Rao, A., R. Forgan-Smith, G. Ritchie, H. Sakellaris, S. Miller, M. Arghyros. 1988. A serendipitous isolate of *Histoplasma capsulatum*. Pathology 20:191-193.
30. Reiss, E., H., H. Hutchinson, L. Pine, D. W. Zeigler, and L. Kaufman. 1977. Solid-phase competitive-binding radioimmunoassay for detecting antibody to the M antigen of histoplasmin. J. Clin. Microbiol. 6:598-604.
31. Saiki, R. K., D. H. Gelfand, S. Stoffel, S. Scharf, R. Higuchi, G. T. Horn, K. B. Mullis, and H. A. Erlich. 1988. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:489-491.

32. Sanger, F., S. Nicklen, and A. R. Coulson. 1977.
DNA sequencing with chain terminating inhibitors.
Proc. Natl. Acad. Sci. USA. 74:5463-5467.
33. Schwarz, L. 1981. Histoplasmosis. Praeger Science
5 Press, New York.
34. Spitzer, E. D., E. J. Keith, S. J. Travis, A. A.
Painter, G. S. Kobayashi, and G. Medoff. 1990.
Temperature-sensitive variants of *Histoplasma*
capsulatum isolated from patients with acquired
10 immunodeficiency syndrome. J. Infect. Dis. 162:258-
261.
35. Towbin, H., T. Staehelin, and J. Gordon. 1979.
Electrophoretic transfer of proteins from
polyacrylamide gels to nitrocellulose sheets:
15 procedure and some applications. Proc. Natl. Acad.
Sci. USA. 76:4350-4354.
36. Vijayakumar, B., G. Medoff, G. S. Kobayashi, and W.
L. Sieling. 1985. Cross-reacting human and rabbit
antibodies to antigens of *Histoplasma capsulatum*,
20 *Candida albicans*, and *Saccharomyces cerevisiae*.
Infect. Immun. 48:806-812.
37. Von Heijne, G. 1986. A new method for predicting
signal sequence cleavage sites. Nucleic Acids Res.
14:4683-4690.
- 25 38. Wheat, L. J., R. B. Kohler, M. L. V. French, J.
Garten, A. White, and Z. Brahmi. 1983. IgM and IgG
histoplasma antibody response in histoplasmosis.
Am. Rev. Resp. Dis. 128:65-70.

39. Wheat L. J., R. B. Kohler, and R. P. Tiwari. 1986. Diagnosis of disseminated histoplasmosis by detection of *Histoplasma capsulatum* antigen in serum and urine specimens. N. Eng. J. Med. 314:83-88.
- 5 40. Wheat L. J., P. Connolly-Stringfield, R. B. Kohler, P. T. Frame, and M. R. Gupta. 1989. *Histoplasma capsulatum* polysaccharide antigen detection in diagnosis and management of disseminated histoplasmosis in patients with AIDS. Am. J. Med. 87:396-400.
- 10 41. Wheat, L. J., R. B. Kohler, R. P. Tiwari, M. Garten, and M. L. V. French. 1989. Significance of *Histoplasma* antigen in the cerebrospinal fluid of patients with meningitis. Arch. Int. Med. 149:302-304.
- 15

SEQUENCE LISTING

(1) GENERAL INFORMATION:

- (i) APPLICANT: Weil M.D., Gary J.
- (ii) TITLE OF INVENTION: METHODS OF OBTAINING ANTIGENS SPECIFIC FOR FUNGI, ANTIBODIES FOR SUCH ANTIGENS, AND DIAGNOSIS OF DISEASE USING SUCH ANTIGENS AND/OR ANTIBODIES
- (iii) NUMBER OF SEQUENCES: 3
- (iv) CORRESPONDENCE ADDRESS:
 - (A) ADDRESSEE: Senniger, Powers, Leavitt and Roedel
 - (B) STREET: One Metropolitan Square- 16th floor
 - (C) CITY: St. Louis
 - (D) STATE: Missouri
 - (E) COUNTRY: USA
 - (F) ZIP: 63102
- (v) COMPUTER READABLE FORM:
 - (A) MEDIUM TYPE: Floppy disk
 - (B) COMPUTER: IBM PC compatible
 - (C) OPERATING SYSTEM: PC-DOS/MS-DOS
 - (D) SOFTWARE: PatentIn Release #1.0, Version #1.25
- (vi) CURRENT APPLICATION DATA:
 - (A) APPLICATION NUMBER:
 - (B) FILING DATE:
 - (C) CLASSIFICATION:
- (viii) ATTORNEY/AGENT INFORMATION:
 - (A) NAME: Stone, Paul A.
 - (B) REGISTRATION NUMBER: 38,628
 - (C) REFERENCE/DOCKET NUMBER: BJCH 9986
- (ix) TELECOMMUNICATION INFORMATION:
 - (A) TELEPHONE: 314-231-5400
 - (B) TELEFAX: 314-231-4342

(2) INFORMATION FOR SEQ ID NO:1:

- (i) SEQUENCE CHARACTERISTICS:
 - (A) LENGTH: 810 base pairs
 - (B) TYPE: nucleic acid
 - (C) STRANDEDNESS: double
 - (D) TOPOLOGY: linear
- (ii) MOLECULE TYPE: cDNA to mRNA
- (vi) ORIGINAL SOURCE:
 - (A) ORGANISM: Histoplasma Capsulatum
- (viii) POSITION IN GENOME:

(B) MAP POSITION: ...

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

ACACAGCATA ACAGAAGATC TCTGAAATTG ACAAAAATGA AAACCATTG CTTGCCTGCT	60
TACTTCAAGC TTCTCTCTTT TCTGTCTGCT ATAGCTGTGA CATCTGGAGC AGCTGTTGAC	120
TCCTGTCTCT TAGAATCAAA CTGCCCACCG CCAACAACAA CAACGACAAC AACGACAACA	180
ACACCAACAC CAACACCAAC ATCAATAATA CCAATAACAC CAATAGTACC AGCAAATAAG	240
ACAATTGTGC TTACAACCAC TATTGAGCCT GGGCCAGGCC AGGTTTGGGC GCAAATAGAG	300
GAGATTGATC CTGAACCATA TTATGTTAGA TGGGTCCCTG ATCCAACGTT TGCCACGCCT	360
GTTGTACTGC ACAATAACAC AGATCTTGTC TTCATGGATG GAAGCAAATC TTTTATCTC	420
AACTTCGATA ACAGCACCTC TGACACGGGT ATTTATTTTG TGAACCTTAA CTCCAACGCT	480
GGTATTAGTC AACTCTATAA GGATAGTGAC AACAAGTTGC TCTGGGGTGG AGCTCAACAA	540
GAGCGGGATG GCTGGATGTG GTGCTTCATG GTCGATCTAC AATACCGCAT GTTCTATTCT	600
GACAGTAAAT TCGTTGGTTC TCCAAGGGAT TGTGGCCTCT CCTCTGTCTT TTTGACAGAG	660
CGCCCGAGTT GAAACAGCTA TTGTGAGGAG GGGAGCAGTT CTGGACCGGC CGTGCGAAAT	720
AAGTAATGAG TATCAAAGTG TTTCTGTGAT CTATGAAATT TAGAGGGCCA GGATACAATT	780
ATTGATCAAC TCCCACAAAA AAAAAAAAAA	810

(2) INFORMATION FOR SEQ ID NO:2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 631 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Histoplasma Capsulatum

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

ATGAAAACCA TTTGCTTGCC TGCTTACTTC AAGCTTCTCT CTTTTCTGTC TGCTATAGCT	60
GTGACATCTG GAGCAGCTGT TGACTCCTGT CTCTTAGAAT CAACTGCCC ACCGCCAACA	120
ACAACAACGA CAACAACGAA CACCAACACC AACACCAACA TCAATAATAC CAATAACACC	180
AATAGTACCA GCAAATAAGA CAATTGTGCT TACAACCACT ATTGAGCCTG GGCCAGGCCA	240

55

```

GGTTTGGGCG CAAATAGAGG AGATTGATCC TGAACCATAT TATGTTAGAT GGGTCCCTGA      300
TCCAACGTTT GCCACGCCTG TTGTACTGCA CAATAACACA GATCTTGTCT TCATGGATGG      360
AAGCAAATCT TTTTATCTCA ACTTCGATAA CAGCACCTCT GACACGGGTA TTTATTTTGT      420
GAACCTTAAC TCCAACGCTG GTATTAGTCA ACTCTATAAG GATAGTGACA ACAAGTTGCT      480
CTGGGGTGGA GCTCAACAAG AGCGGGATGG CTGGATGTGG TGCTTCATGG TCGATCTACA      540
ATACCGCATG TTCTATTCTG ACAGTAAATT CGTTGGTTCT CCAAGGGATT GTGGCCTCTC      600
CTCTGTCTTT TTGACAGAGC GCCCGAGTTG A                                     631

```

(2) INFORMATION FOR SEQ ID NO:3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 211 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:3:

```

Met Lys Thr Ile Cys Leu Pro Ala Tyr Phe Lys Leu Leu Ser Phe Leu
1           5           10           15
Ser Ala Ile Ala Val Thr Ser Gly Ala Ala Val Asp Ser Cys Leu Leu
20           25           30
Glu Ser Asn Cys Pro Pro Pro Thr Thr Thr Thr Thr Thr Thr Thr
35           40           45
Thr Pro Thr Pro Thr Pro Thr Ser Ile Ile Pro Ile Thr Pro Ile Val
50           55           60
Pro Ala Asn Lys Thr Ile Val Leu Thr Thr Thr Ile Glu Pro Gly Pro
65           70           75           80
Gly Gln Val Trp Ala Gln Ile Glu Glu Ile Asp Pro Glu Pro Tyr Tyr
85           90           95
Val Arg Trp Val Pro Asp Pro Thr Phe Ala Thr Pro Val Val Leu His
100          105          110
Asn Asn Thr Asp Leu Val Phe Met Asp Gly Ser Lys Ser Phe Tyr Leu
115          120          125
Asn Phe Asp Asn Ser Thr Ser Asp Thr Gly Ile Tyr Phe Val Asn Leu
130          135          140

```

56

Asn	Ser	Asn	Ala	Gly	Ile	Ser	Gln	Leu	Tyr	Lys	Asp	Ser	Asp	Asn	Lys
145					150					155					160
Leu	Leu	Trp	Gly	Gly	Ala	Gln	Gln	Glu	Arg	Asp	Gly	Trp	Met	Trp	Cys
				165					170					175	
Phe	Met	Val	Asp	Leu	Gln	Tyr	Arg	Met	Phe	Tyr	Ser	Asp	Ser	Lys	Phe
			180					185					190		
Val	Gly	Ser	Pro	Arg	Asp	Cys	Gly	Leu	Ser	Ser	Val	Phe	Leu	Thr	Glu
		195					200					205			
Arg	Pro	Ser													
	210														

WE CLAIM:

1. A method for identifying a protein antigen of a target fungus, the method comprising
obtaining a cDNA gene expression library for the target fungus,
5 expressing target-fungus proteins from the cDNA gene expression library,
obtaining antisera to the target fungus, the antisera comprising target-fungus antibodies,
obtaining antisera to a nontarget fungus having at
10 least one antigenic determinant in common with the target fungus, the antisera comprising nontarget-fungus antibodies, and
identifying a target-fungus protein which is bound by the target-fungus antibodies, but which is not
15 substantially bound by the nontarget-fungus antibodies.
2. The method of claim 1 wherein the nontarget fungus is a first nontarget fungus and further comprising
obtaining antisera to a second nontarget fungus having at least one antigenic determinant in common with
5 the target fungus, the antisera comprising second nontarget-fungus antibodies, and
identifying a target-fungus protein which is bound by the target-fungus antibodies, but which is not
substantially bound by the second nontarget-fungus
10 antibodies.
3. The method of claim 1 wherein the target fungus is an ascomycete or an imperfect fungus.
4. The method of claim 1 wherein the target fungus is in the Gymnoascaceae family.
5. The method of claim 1 wherein the target fungus is in the genus *Ajellomyces*.

6. The method of claim 1 wherein the target fungus is *H. capsulatum* and the nontarget fungi are selected from the group consisting of *Coccidioides immitis*, *Blastomyces dermatitidis* and *Candida sp.*

7. The method of claim 1 wherein the immunoreactivity of the nontarget-fungus antibodies with the target-fungus protein is less than about 10% of the immunoreactivity of the target-fungus antibodies with the
5 target-fungus protein.

8. The method of claim 1 wherein the immunoreactivity of the nontarget-fungus antibodies with the target-fungus protein is less than about 1% of the immunoreactivity of the target-fungus antibodies with the
5 target-fungus protein.

9. The method of claim 1 wherein the cDNA gene expression library for the target fungus is a λ phage library.

10. The method of claim 1 wherein the target-fungus antisera and the nontarget-fungus antisera are obtained from vertebrates infected with the target fungus and the nontarget fungus, respectively.

11. The method of claim 1 wherein the target-fungus antisera and the nontarget-fungus antisera are obtained from vertebrates immunized with the target fungus and the nontarget fungus, respectively.

12. A substantially purified antibody or antibody fragment which is immunoreactive with a protein antigen identified according to the method of claim 1.

13. The antibody of claim 12 wherein the antibody is a polyclonal antibody.

14. The antibody of claim 12 wherein the antibody is a monoclonal antibody.

15. The antibody of claim 12 wherein the antibody is a recombinant antibody.

16. A substantially purified antibody or antibody fragment which is immunoreactive with an antigen of *H. capsulatum*, but which is not substantially immunoreactive with antigens of each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.*

17. The antibody or antibody fragment of claim 16 wherein the *H. capsulatum* antigen has an amino acid sequence that includes a portion of the amino acid sequence set forth in SEQ ID NO: 3, the included portion being bound by antibodies to *H. capsulatum* but not being substantially bound by antibodies to each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.*

18. The antibody of claim 16 wherein the antibody is a polyclonal antibody.

19. The antibody of claim 16 wherein the antibody is a monoclonal antibody.

20. The antibody of claim 16 wherein the antibody is a recombinant antibody.

21. A substantially purified antibody or antibody fragment which is immunoreactive with a protein antigen having the amino acid sequence set forth in SEQ ID NO: 3.

22. The antibody of claim 21 wherein the antibody is a polyclonal antibody.

23. The antibody of claim 21 wherein the antibody is a monoclonal antibody.

24. The antibody of claim 21 wherein the antibody is a recombinant antibody.

25. A method for determining the presence or absence of a target-fungus antibody in a vertebrate, the method comprising

5 obtaining an antibody-containing sample from the vertebrate,

contacting the sample with a target-fungus protein antigen identified according to the method of claim 1, and

10 determining whether an antibody in the sample immunoreacts with the target-fungus protein antigen.

26. The assay of claim 25 wherein the vertebrate is a mammal.

27. The assay of claim 25 wherein the vertebrate is a human.

28. A method for determining the presence or absence of *H. capsulatum* antibodies in a mammal, the method comprising

5 obtaining an antibody-containing sample from the mammal,

contacting the sample with a protein antigen of *H. capsulatum* which is bound by antibodies to *H. capsulatum* but which is not substantially bound by antibodies to each of *Coccidioides immitis*, *Blastomyces dermatitidis* or
10 *Candida sp.*, and

determining whether an antibody in the sample immunoreacts with the protein antigen of *H. capsulatum*.

29. The method of claim 28 wherein the *H. capsulatum* protein antigen has an amino acid sequence that includes a portion of the amino acid sequence set forth in SEQ ID NO: 3, the included portion being bound by antibodies to
5 *H. capsulatum* but not being substantially bound by antibodies to each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.*

30. The assay of claim 28 wherein the mammal is a human.

31. The method of claim 28 wherein the immunoreactivity of the nontarget-fungus antibodies with the target-fungus protein is less than about 10% of the immunoreactivity of the target-fungus antibodies with the
5 target-fungus protein.

32. The method of claim 28 wherein the immunoreactivity of the nontarget-fungus antibodies with the target-fungus protein is less than about 1% of the immunoreactivity of the target-fungus antibodies with the
5 target-fungus protein.

33. A method for determining the presence or absence of *H. capsulatum* antibodies in a mammal, the method comprising

obtaining an antibody-containing sample from the
5 mammal,

contacting the sample with a protein antigen having an amino acid sequence as set forth in SEQ ID NO: 3, and determining whether an antibody in the sample immunoreacts with the protein antigen.

34. The assay of claim 33 wherein the mammal is a human.

35. A method for determining the presence or absence of a target-fungus protein antigen in a sample, the method comprising

5 obtaining a sample to be tested for the presence or absence of the target-fungus protein antigen,

contacting the sample with an antibody or antibody fragment which is immunoreactive with a target-fungus protein antigen identified according to the method of claim 1, and

10 determining whether the antibody or antibody fragment immunoreacts with the target-fungus protein antigen.

36. The assay of claim 35 wherein the sample is obtained from a vertebrate.

37. The assay of claim 35 wherein the sample is obtained from a mammal.

38. The assay of claim 35 wherein the sample is obtained from a human.

39. The assay of claim 35 wherein the sample is obtained from a plant, a food, a feed or a feed component.

40. A method for determining the presence or absence of a *H. capsulatum* protein antigen in a mammal, the method comprising:

- 5 obtaining a sample to be tested for the presence or absence of the *H. capsulatum* protein antigen,
contacting the sample with an antibody or antibody fragment which is immunoreactive with an antigen of *H. capsulatum*, but which is not substantially immunoreactive with antigens of each of *Coccidioides immitis*,
10 *Blastomyces dermatitidis* or *Candida sp.*, and
determining whether the antibody or antibody fragment immunoreacts with the *H. capsulatum* protein antigen.

41. The method of claim 40 wherein the antibody or antibody fragment is immunoreactive with a *H. capsulatum* protein antigen having an amino acid sequence that includes a portion of the amino acid sequence set forth
5 in SEQ ID NO: 3, the included portion being bound by antibodies to *H. capsulatum* but not being substantially bound by antibodies to each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.*

42. The assay of claim 40 wherein the mammal is a human.

43. The method of claim 40 wherein the immunoreactivity of the nontarget-fungus antibodies with the target-fungus protein is less than about 10% of the immunoreactivity of the target-fungus antibodies with the
5 target-fungus protein.

44. The method of claim 40 wherein the immunoreactivity of the nontarget-fungus antibodies with the target-fungus protein is less than about 1% of the immunoreactivity of the target-fungus antibodies with the target-fungus protein.

45. A method for determining the presence or absence of a *H. capsulatum* protein antigen in a mammal, the method comprising:

obtaining a sample to be tested for the presence or absence of the *H. capsulatum* protein antigen,

5 contacting the sample with an antibody or antibody fragment which is immunoreactive with a protein antigen having an amino acid sequence as set forth in SEQ ID NO: 3, and

10 determining whether the antibody or antibody fragment immunoreacts with the protein antigen.

46. The assay of claim 45 wherein the mammal is a human.

47. A kit comprising

a reagent selected from the group consisting of (i) a target-fungus protein antigen identified according to the method of claim 1, (ii) a fragment of a target-fungus protein antigen identified according to the method of
5 claim 1 wherein the fragment is bound by antibodies to the target fungus but is not substantially bound by antibodies to the nontarget fungus, and (iii) a target-fungus antibody or antibody fragment which immunoreacts
10 with a target-fungus protein antigen identified according to the method of claim 1, and

instructions directing the use of the reagent for determining the presence or absence of the target fungus in a sample.

48. The kit of claim 47 wherein the instructions direct the use of the reagent for determining whether a mammal is presently infected or has been previously infected with the target fungus.

49. The kit of claim 47 wherein the reagent is an antibody and the instructions direct the use of the antibody reagent for determining the presence or absence of an antigen in a plant, food, feed or feed component sample.

50. A kit comprising
a reagent selected from the group consisting of (i) a protein antigen of *H. capsulatum* which is bound by *H. capsulatum* antibodies but which is not substantially bound by antibodies to each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.*, (ii) a fragment of a *H. capsulatum* protein antigen wherein the fragment is bound by antibodies to *H. capsulatum* but is not substantially bound by antibodies to each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.*, and (iii) an antibody or antibody fragment which is immunoreactive with a *H. capsulatum* protein antigen but which is not substantially immunoreactive with antigens of each of *Coccidioides immitis*, *Blastomyces dermatitidis* or *Candida sp.*, and instructions directing the use of the reagent for determining the presence or absence of *H. capsulatum* antibodies in a sample.

51. The kit of claim 50 wherein the instructions direct the use of the reagent for determining whether a mammal is presently infected or has been previously infected with *H. capsulatum*.

52. A kit comprising
a reagent selected from the group consisting of (i)
a protein antigen having an amino acid sequence as set
forth in SEQ ID NO:3, (ii) a protein antigen that
5 includes a portion of the amino acid sequence as set
forth in SEQ ID NO:3 wherein the included portion is
bound by antibodies to *H. capsulatum* but is not
substantially bound by antibodies to each of *Coccidioides*
immitis, *Blastomyces dermatitidis* or *Candida sp.*, (iii)
10 an antibody or antibody fragment which is immunoreactive
with a protein antigen having the amino acid sequence set
forth in SEQ ID NO: 3, and (iv) an antibody or antibody
fragment which is immunoreactive with a protein antigen
that includes a portion of the amino acid sequence set
15 forth in SEQ ID NO: 3 wherein the included portion is
bound by antibodies to *H. capsulatum* but is not
substantially bound by antibodies to each of *Coccidioides*
immitis, *Blastomyces dermatitidis* or *Candida sp.*, and
instructions directing the use of the reagent for
20 determining the presence or absence of *H. capsulatum*
antibodies in a sample.

53. The kit of claim 52 wherein the instructions
direct the use of the reagent for determining whether a
vertebrate is presently infected or has been previously
infected with *H. capsulatum*.

19/4

GH17 38 PPTTTTTTTTTTPTPTTSIIPITP 62
 P + T T T T TPPTPT TP
Cellulase 329 PTSTVTPTPTPTPTPTVATPTP 353

[illegible]

GH17
Xenopus

22	TSGAAVDSCLLESNCPPPTTTTTTTTTTTTTPPTTSIIPIPTPIVPANKTIVLTITTIETP	78
418	T+ A + + P TTTTTTTT T TPT+ P T A T TTT P TKATATTTTPTTTTTTPTTTTTTTTTTKATTTTPTTTTTTPTTTTTTPTTTTTTPT	474

FIG. 2





FIG. 3



BEST AVAILABLE COPY

4/6

FIG. 4B





FIG. 4A




BEST AVAILABLE COPY

SUBSTITUTE SHEET (RULE 26)


BEST AVAILABLE COPY

FIG. 5A

A




B



SUBSTITUTE SHEET (RULE 26)

FIG. 6



BEST AVAILABLE COPY

SUBSTITUTE SHEET (RULE 26)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/07728

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : Please See Extra Sheet.

US CL : Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.74; 435/7.1, 7.31, 7.92, 7.93, 7.94, 7.95, 69.1, 240.2, 254.1, 254.11, 254.22, 341; 530/350, 387.1, 388.2, 388.5

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, WPIDS, CAPLUS, MEDLINE, EMBASE, BIOSIS, CABA, AGRICOLA

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHANDRASHEKAR, R. et al. Molecular cloning and characterization of recombinant parasite antigens for immunodiagnosis of onchocerciasis. J. Clin. Invest. November 1991, Vol. 88, pages 1460-1466, see entire document.	1-15, 25-27, 35-39, 47-49
Y	ZIMMERMANN, R. C. et al. Cloning and expression of the complement fixation antigen-chitinase of Coccidioides immitis. Infection and Immunity. December 1996, Vol. 64, No. 12, pages 4967-4975, see entire document.	1-15, 35-39, 47-49

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
B earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*Z* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

13 JULY 1998

Date of mailing of the international search report

19 AUG 1998

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

KHALID MASOOD

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

 International application No.
 PCT/US92/07728

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KAUFMAN, L. Laboratory methods for the diagnosis and confirmation of systemic mycoses. Clin. Infec. Dis. 1992, Vol. 14 (Suppl I), pages S23-S29, see entire document.	1-15, 25-27, 35-39, 47-49
Y	KUMAR, V. B. Cross-reacting human and rabbit antibodies to antigens of Histoplasma capsulatum, Candida albicans, and Saccharomyces cerevisiae. June 1985, Vol. 48, No. 3, pages 806-812, see entire document.	1-15, 25-27, 35-39, 47-49
Y	CHANDRASHEKAR, R. et al. Molecular cloning of Brugia malayi antigens for diagnosis of lymphatic filariasis. Mol. and Biochem. Parasitol. 1994, Vol. 64, pages 261-271, see entire document.	1-15, 25-27, 35-39, 47-49
Y	GALFRE, G. et al. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature. 07 April 1977, Vol. 266, pages 550-552, see entire document.	12-15
Y	LOWMAN, B. H. et al. Selecting high-affinity binding proteins by monovalent phage display. Biochemistry. 1991, Vol. 30, pages 10832-10838, see entire document.	15
Y	WHEAT, J. L. et al. Diagnosis of disseminated histoplasmosis by detection of histoplasma capsulatum antigen in serum and urine species. New Eng. J. Med. 09 January 1986, Vol. 314, No. 2, pages 83-88, see entire document.	1-15, 25-27, 35-39, 47-49
Y	GEORGE, B. R. et al. Radioimmunoassay: a sensitive screening test for histoplasmosis and blastomycosis. Am. Rev. Resp. Dis. October 1981, Vol. 124, No. 4, pages 407-410, see entire document.	12-14, 25-27, 35-39, 47-49
A	KWAN-CHUNG, J. K. Emmonsella capsulata: perfect state of histoplasma capsulatum. Science. 28 July 1972, Vol. 177, pages 368-369, see entire document.	1-15, 25-27, 35-39, 47-49

Form PCT/ISA/210 (continuation of second sheet)(July 1992)*

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/07728

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-15, 25-27, 35-39, 47-49

Remark on Protest

☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US98/07728

A. CLASSIFICATION OF SUBJECT MATTER: IPC (6):

C12N 15/04, 15/11, 1/14; G01N 33/53; C07K 14/00, 14/37, 16/00, 16/14

A. CLASSIFICATION OF SUBJECT MATTER: US CL :

536/23.74; 435/7.1, 7.31, 7.92, 7.93, 7.94, 7.95, 69.1, 240.2, 254.1, 254.11, 254.22, 341; 530/350, 387.1, 388.2, 388.5

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s) 1-11, 12-15, 25-27, 35-39, 47-49, drawn to a method for identifying a protein antigen of a target fungus from cDNA expression library, antibody, a method for determining the antibody, a method for determining the presence or absence of a target fungus protein and a kit.

Group II, claim(s) 16-24, 28-34, 50-51, drawn to a purified antibody, a method for determining the presence or absence of H. capsulatum antibodies and kit.

Group III, claim(s) 40-46, 52-53, drawn to a method for determining the presence or absence of a H. capsulatum protein antigen and kit.

The inventions listed as Groups I, II and III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the special technical feature of Group I invention is the method for identifying a protein antigen of a target fungus from cDNA expression library therein, the special technical feature of Group II invention is the purified antibody therein while the special technical feature of Group III invention is the method for determining the presence or absence of a H. capsulatum protei. Since the special technical feature of Group I invention is not present in the Group II claims and special technical feature of Group II invention is not present in the Group I claims and special technical feature of Group III invention is not present in Group I claims and special technical feature of Group I invention is not present in Group II and III claims, unity of invention is lacking.